Loading
CRG-023 is an experimental autologous tri-specific CAR T-cell therapy from CARGO Therapeutics, in preclinical development for large B-cell lymphoma; its current status is not stated.
CRG-023 is an autologous tri-specific CAR T-cell therapy from CARGO Therapeutics. T cells carrying three separate CARs against CD19, CD20 and CD22 expressed from one lentiviral vector, each with its own co-stimulatory domain, including a CD2 co-stimulatory domain. Its furthest stage is preclinical development, for large B-cell lymphoma. No clinical trial naming it is registered on ClinicalTrials.gov. FDA allowed the IND in January 2025; in March 2025 the board suspended various development efforts and the company was later acquired. No trial registered. It has not been shown to work in people.
1.CRG-023 slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CRG-023" OR ABSTRACT:"CRG-023") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CRG-023, not a curated reading list.
Shares CARGO Therapeutics and the tag pipeline.
Shares CARGO Therapeutics, CD22 and the tag pipeline.
Shares CD19 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/